Myriad Genetics' Stock Crashes 70%—What's Next for the Biotech Firm?
Myriad Genetics, a key player in genetic testing and precision medicine, has faced a sharp drop in its stock value. Over the past year, shares fell by over 70%, with prices tumbling from nearly $30 to just above $5 by mid-2025. The company is now preparing to discuss its financial performance in an upcoming earnings call.
The firm will release its fourth-quarter and full-year 2025 earnings on Monday, February 23, 2026, after the market closes. A live webcast of the earnings conference call will follow at 4:30 pm ET, available on Myriad's Investor Relations website.
In early March, executives will also take part in two major healthcare conferences. President and CEO Sam Raha, alongside CFO Ben Wheeler, will first speak at the TD Cowen 46th Annual Health Care Conference on March 3 at 3:10 pm ET. A week later, they will present at the Leerink Partners Global Healthcare Conference on March 10 at 1:40 pm ET.
The company's stock performance in 2025 reflected significant challenges. By June 18, 2025, the share price had plunged to around $5.09, a steep decline from its 52-week high of approximately $29.28. This marked a 12-month loss of 72.71% by early 2026.
Myriad Genetics will address its financial results and future outlook in the upcoming earnings call. Investors and industry analysts will likely focus on the reasons behind the stock's steep decline. The company's participation in high-profile healthcare conferences may provide further insights into its strategic direction.
